In the ever-evolving landscape of pharmaceutical development, excipient formulation strategies have become a critical focus for new developers. As the industry grapples with increasingly complex drug molecules and delivery challenges, innovative approa…
The biotech industry is known for its high-risk, high-reward nature, with early-stage companies facing significant challenges in securing funding to
Enantiomer Switching: A Pharmaceutical Strategy to Extend Drug Patents Enantiomer switching, also known as chiral switching, is a strategy employed […]
Source
The Chiral Switch: A Pharmaceutical Tactic to Prolong Exclusivity Read Post »
Annual Drug Patent Expirations for LUMAKRAS Lumakras is a drug marketed by Amgen Inc and is included in one NDA. […]
Source
Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one […]
Source
Annual Drug Patent Expirations for RUBRACA Rubraca is a drug marketed by Zr Pharma and is included in one NDA. […]
Source
New patent expiration for Zr Pharma drug RUBRACA Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
A strong patent portfolio is at the core of branded pharmaceutical firms. Accordingly, one way to assess the relative strength […]
Source
Which pharmaceutical companies have the largest patent portfolios? Read Post »
In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating […]
Source
Cracking the Biosimilar Code: A Deep Dive into Effective IP Strategies Read Post »
Intellectual property (IP) strategy plays a crucial role in the biotechnology industry, where protecting valuable assets and driving innovation are
Get new actionable insights and updates from BiotechBlog
